Transforming Sickle Cell Care Through Federal Advocacy

KMDA is dedicated to creating meaningful changes in sickle cell care through federal legislative and policy advocacy. By working closely with policymakers, healthcare professionals, and community advocates, we strive to secure a future where those affected by sickle cell disease have access to the care, treatment, and support they deserve.

Our 2024 Milestones

KMDA spearheaded the introduction of the Sickle Cell Disease Treatment Centers Act of 2024, aiming to improve access to comprehensive care. The organization also played a key role in organizing the inaugural Sickle Cell Summit led by the U.S. Secretary of Health, which brought together over 400 participants to discuss critical next steps for sickle cell care. Additionally, KMDA was appointed to the CDC’s Sickle Cell Data Collection national team, contributing to essential data-driven policy improvements.

Our Mission

Our Key Advocacy Goals

Charity is a dynamic and forward-thinking charity donation organization committed to making a positive impact on communities around the world.

Why Choose Us
Secure Federal Funding

Advocate for increased funding for research, treatment, and comprehensive healthcare services for sickle cell patients.

Expand Healthcare Access

Establish specialized treatment centers and improve healthcare access for underserved communities.

Prioritize Sickle Cell in Public Health

Promote sickle cell as a national public health priority.

Address Workforce Shortages

Support training for healthcare providers.

Meet our team

Meet All Members
Kimberley Davis

Founder & Executive Director

Dr. Michael Thompson

Chief Medical Officer

volunteer
Emily Rodriguez

Director of Community Outreach

Jessica Lee

Volunteer Coordinator

How can we help you make transformative change?

At KMD Advocacy Center, we believe that the power of compassion and generosity can drive transformative change for those affected by sickle cell disease. Your support is crucial in helping us advance our mission and make a meaningful impact on the lives of individuals and families in need.

Donate

Contribute financially to support our advocacy, research, and community programs.

Advocate

Join our campaigns to promote legislative changes and increased funding for sickle cell care and research.

Contribute financially to support our work increasing the federal investment, equity in treatment and care, as well as accurate data to guide investments in programs.

The actual numbers of individuals with sickle cell has not been determined but is in the millions worldwide. People from varying ethnic and racial backgrounds are living with sickle cell including individuals of African American, Greek, Latino, SE Asian, African, Middle Eastern, Caribbean, Central and South America and other European ethnicities.

Central and South America and other European ethnicities.

background

While the life expectancy of patients with sickle cell disease has increased with improved childhood treatment, many lack access to specialized providers needed who have an understanding of chronic multidisciplinary care management. Even in the United States equity of care and lack of access to care and shortages of transition to adulthood programs are prevalent.

care and shortages of transition to adulthood programs are prevalent.

background

Sickle Cell disease is one of the most common inherited blood disorders in the United States, but the exact number of people living with sickle cell disease and sickle cell trait are unknown.

living with sickle cell disease and sickle cell trait are unknown.

background

Significant disparities exist for funding for inherited blood disorders. Although sickle cell is three times as prevalent as cystic fibrosis, NIH funding cystic fibrosis was $2807 per person vs $812 per person for sickle cell.  In philanthropy $7,690 was spent per person with cystic fibrosis vs $102 per person with for sickle cell. This also translates into less research dollars and less discoveries of new treatments. (Farooq, Mogayzel and Lanzkron: JAMA Network Open, 2020:3)

(Farooq, Mogayzel and Lanzkron: JAMA Network Open, 2020:3)

background

If individuals and families living with sickle cell are afforded equitable care, treatment and employment opportunities this would also translate into increased economic contributions to the communities, states and nation in which they live. 

the communities, states and nation in which they live. 

background